Intravenous repeated

Dose. Aldosterone has been given in doses of 500 pg intravenously, repeated several times a day. 

Dose. Bemegride has been given in doses of 25 to 50 mg intravenously, repeated as necessary. 

Dose. 0.5 to 1 mg of levallorphan tartrate intravenously, repeated if necessary. 

Usual measures for decontamination (ipecac/lavage, activated charcoal, cathartics) are recommended within 2h of ingestion. Renal and hepatic function should be monitored and supported. If acidosis occurs, treatment should begin with 1 or 2 mEq kg (for children ImEqkg ) of sodium bicarbonate intravenously, repeated every 1 or 2 h as needed. Hemodialysis may be necessary for severe acid/base disturbances or renal failure. Treatment with ethanol has been effective in animals, but efficacy data for humans are not available. 

RESPIRATORY PARALYSIS Treatment of respiratory paralysis arising from an adverse reaction or overdose of a neuromuscular blocking agent includes positive-pressure artificial respiration with oxygen and maintenance of a patent airway until recovery of normal respiration is ensured. With the competitive blocking agents, this may be hastened by the administration of neostigmine methylsulfate (0.5-2 mg intravenously) or edrophonium (10 mg intravenously, repeated as required). 

Notify a physician immediately. A suggested procedure for physicians or nurses is intravenous administration of 0.3 g (10 mL of a 3% solution) of sodium nitrite at the rate of 2.5 mL/min followed by 12.5 g (50 mL of a 25% solution) of sodium thiosulfate at the same rate. Watch the patient for 24 to 48 h, especially in cases of ingestion or skin absorption. If symptoms reappear, repeat the injections in half the original amounts. These solutions should be kept readily available. In some cases, first aid personnel have been trained to use the intravenous medication subject to government regulations. 

Intravenous infusion of epinephrin 0.1-0.5 mg epinephrin dissolved in plasma replacement, this can be repeated after 5 min. 

Dibutyltin dichloride induced acute pancreatitis and bile duct lesions in rats, depending on dose (6 and 8 mg/kg body weight intravenously) and time (1-24 weeks) (Merkord Hennighausen, 1989 Merkord et al., 1997, 1999 Sparmann et al., 2001). The lesions in the pancreas developed into a pancreatic fibrosis, and the lesions in the liver into liver cirrhosis. A single intravenous administration of dibutyltin dichloride at 4 mg/kg body weight induced a mild interstitial pancreatitis after 2 days (Merkord et al., 2001). Repeated administration of dibutyltin dichloride (4 mg/kg body weight intravenously) to rats at intervals of 3 weeks induced acute interstitial pancreatitis and, after 9-12 weeks, a pancreatic fibrosis and liver lesions (intrahepatic bile duct hyperplasia) (Merkord et al, 2001). 

Data on the biocompatibility of gelatin microspheres is extremely limited. Drug-free microspheres elicited no untoward effects when injected intravenously into mice over a 12-week period (159). When albumin microspheres were injected repeatedly into the knee joints of rabbits, pronounced rapid joint swelling occurred after the second and subsequent injections. By comparison, no swelling occurred when gelatin microspheres were administered (160). 

Previous reactors are at high risk for a new reaction. In many cases reported, re-administration of the culprit contrast medium to patients with a previous non-immediate exanthema resulted in a repeat reaction [1]. In some (but not all) cases, a more severe reaction with subsequent RCM exposure has been described. After provocation tests, a re-appearance of the exanthemas after intravenous administration of the culprit contrast medium has been reported in patients with previous contrast medium-induced eruptions [1]. 

FIGURE 2.6 Dynamic susceptibility contrast imaging. Axial images of the brain are acquired repeatedly, in this case every 1.5 seconds. As a bolus of intravenously injected contrast material enters the brain, first arteries, then brain parenchyma, and finally veins demonstrate a transient loss of signal intensity. In this acute stroke patient, hypoperfusion of the left middle cerebral artery territory results in delayed arrival of the contrast bolus and prolonged stasis of contrast within the tissue. 

One-compartment open model for repeated intravenous administration... 

Fig. 39.11. (a) One compartment open model for repeated intravenous injection of the same dose D at constant intervals 0. (b) Time course of the plasma concentration Cp with peaks C and troughs C at multiples of the time interval 0. Tlie peaks and troughs tend asymptotically toward the... 

Epinephrine 1 mg intravenous push (IVP), repeat every 3-5 min or Vasopressin 40 units IVP x one dose only (replace first or second dose of epinephrine)... 

D 1 mg slow intravenous push (IVP), repeated every 5 min. Not to exceed a total of 5 mg D An alternative dosing regimen may be 0.1 mg/kg in three divided doses every 2-3 min. Do not exceed a rate of 1 mg/min o Contraindications... 

Ondansetron (Zofran) 32 mg intravenously prior to chemotherapy as a single dose, or 0.1 5 mg/kg prior to chemotherapy, repeat at 4 and 8 hours or 8 mg orally 30 minutes prior to chemotherapy, repeat at 4 and 8 hours and every 12 hours for 1 -2 days after chemotherapy completion ... 

Desmopressin (DDAVP) increases the release of factor VIII (von Willebrand factor) from endothelial tissue in the vessel wall. Bleeding time is promptly reduced, within 1 hour of administration, and is sustained for 4 to 8 hours.42 Doses used for uremic bleeding are 0.3 to 0.4 mcg/kg intravenously over 20 to 30 minutes, 0.3 mcg/kg subcutaneously, or 2 to 3 mcg/kg intranasally. Repeated doses can cause tachyphylaxis by... 

---